Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. - Lundin,J.; Hagberg,H.; Repp,R.; Cavallin-Ståhl,E.; Fredén,S.; Juliusson,G.; Rosenblad,E.; TjÒnnfjord,G.; Wiklund,T.; Österborg,A. (Blood, 2003)